Cargando…

TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines

BACKGROUND: The nerve growth factor (NGF) receptor tyrosine-kinase TrkA is a well-known determinant of the melanocytic lineage, through modulation of the MAPK and AKT cascades. While TrkA gene is frequently rearranged in cancers, its involvement in malignant melanoma (MM) development is still unclea...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasini, Luigi, Re, Angela, Tebaldi, Toma, Ricci, Gianluca, Boi, Sebastiana, Adami, Valentina, Barbareschi, Mattia, Quattrone, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619539/
https://www.ncbi.nlm.nih.gov/pubmed/26496938
http://dx.doi.org/10.1186/s12885-015-1791-y
_version_ 1782397126103269376
author Pasini, Luigi
Re, Angela
Tebaldi, Toma
Ricci, Gianluca
Boi, Sebastiana
Adami, Valentina
Barbareschi, Mattia
Quattrone, Alessandro
author_facet Pasini, Luigi
Re, Angela
Tebaldi, Toma
Ricci, Gianluca
Boi, Sebastiana
Adami, Valentina
Barbareschi, Mattia
Quattrone, Alessandro
author_sort Pasini, Luigi
collection PubMed
description BACKGROUND: The nerve growth factor (NGF) receptor tyrosine-kinase TrkA is a well-known determinant of the melanocytic lineage, through modulation of the MAPK and AKT cascades. While TrkA gene is frequently rearranged in cancers, its involvement in malignant melanoma (MM) development is still unclear. METHODS: We analyzed a dataset of primary cutaneous MM (n = 31) by array comparative genomic hybridization (aCGH), to identify genomic amplifications associated with tumor progression. The analysis was validated by genomic quantitative PCR (qPCR) on an extended set of cases (n = 64) and the results were correlated with the clinical outcome. To investigate TrkA molecular pathways and cellular function, we generated inducible activation of the NGF-TrkA signaling in human MM cell lines. RESULTS: We identified amplification of 1q23.1, where the TrkA locus resides, as a candidate hotspot implicated in the progression of MM. Across 40 amplicons detected, segmental amplification of 1q23.1 showed the strongest association with tumor thickness. By validation of the analysis, TrkA gene amplification emerged as a frequent event in primary melanomas (50 % of patients), and correlated with worse clinical outcome. However, experiments in cell lines revealed that induction of the NGF-TrkA signaling produced a phenotype of dramatic suppression of cell proliferation through inhibition of cell division and pronounced intracellular vacuolization, in a way straightly dependent on NGF activation of TrkA. These events were triggered via MAPK activity but not via AKT, and involved p21(cip1) protein increase, compatibly with a mechanism of oncogene-induced growth arrest. CONCLUSIONS: Taken together, our findings point to TrkA as a candidate oncogene in MM and support a model in which the NGF-TrkA-MAPK pathway may mediate a trade-off between neoplastic transformation and adaptive anti-proliferative response. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1791-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4619539
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46195392015-10-26 TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines Pasini, Luigi Re, Angela Tebaldi, Toma Ricci, Gianluca Boi, Sebastiana Adami, Valentina Barbareschi, Mattia Quattrone, Alessandro BMC Cancer Research Article BACKGROUND: The nerve growth factor (NGF) receptor tyrosine-kinase TrkA is a well-known determinant of the melanocytic lineage, through modulation of the MAPK and AKT cascades. While TrkA gene is frequently rearranged in cancers, its involvement in malignant melanoma (MM) development is still unclear. METHODS: We analyzed a dataset of primary cutaneous MM (n = 31) by array comparative genomic hybridization (aCGH), to identify genomic amplifications associated with tumor progression. The analysis was validated by genomic quantitative PCR (qPCR) on an extended set of cases (n = 64) and the results were correlated with the clinical outcome. To investigate TrkA molecular pathways and cellular function, we generated inducible activation of the NGF-TrkA signaling in human MM cell lines. RESULTS: We identified amplification of 1q23.1, where the TrkA locus resides, as a candidate hotspot implicated in the progression of MM. Across 40 amplicons detected, segmental amplification of 1q23.1 showed the strongest association with tumor thickness. By validation of the analysis, TrkA gene amplification emerged as a frequent event in primary melanomas (50 % of patients), and correlated with worse clinical outcome. However, experiments in cell lines revealed that induction of the NGF-TrkA signaling produced a phenotype of dramatic suppression of cell proliferation through inhibition of cell division and pronounced intracellular vacuolization, in a way straightly dependent on NGF activation of TrkA. These events were triggered via MAPK activity but not via AKT, and involved p21(cip1) protein increase, compatibly with a mechanism of oncogene-induced growth arrest. CONCLUSIONS: Taken together, our findings point to TrkA as a candidate oncogene in MM and support a model in which the NGF-TrkA-MAPK pathway may mediate a trade-off between neoplastic transformation and adaptive anti-proliferative response. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1791-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-24 /pmc/articles/PMC4619539/ /pubmed/26496938 http://dx.doi.org/10.1186/s12885-015-1791-y Text en © Pasini et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pasini, Luigi
Re, Angela
Tebaldi, Toma
Ricci, Gianluca
Boi, Sebastiana
Adami, Valentina
Barbareschi, Mattia
Quattrone, Alessandro
TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
title TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
title_full TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
title_fullStr TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
title_full_unstemmed TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
title_short TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
title_sort trka is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619539/
https://www.ncbi.nlm.nih.gov/pubmed/26496938
http://dx.doi.org/10.1186/s12885-015-1791-y
work_keys_str_mv AT pasiniluigi trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines
AT reangela trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines
AT tebalditoma trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines
AT riccigianluca trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines
AT boisebastiana trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines
AT adamivalentina trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines
AT barbareschimattia trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines
AT quattronealessandro trkaisamplifiedinmalignantmelanomapatientsandinducesanantiproliferativeresponseincelllines